Prescription Drugs - Central Asia

Central Asia

In Central Asia, the Prescription Drugs market is expected to witness a significant increase in revenue.
By the year 2024, the projected revenue is estimated to reach US$0.77bn.
Furthermore, it is anticipated that the market will exhibit a compound annual growth rate (CAGR 2024-2029) of 2.71%, resulting in a market volume of US$0.88bn by 2029.
When comparing the revenue on a global scale, it is worth noting that United States is expected to generate the highest revenue in the Prescription Drugs market.
In 2024 alone, the revenue United States is projected to reach a staggering US$358.90bn.
In terms of per person revenues in Central Asia, it is estimated that in 2024, each individual will generate revenues of US$9.70.
This figure provides insight into the market's performance relative to the total population.
Central Asia's prescription drug market is experiencing a surge in demand due to an aging population and increasing prevalence of chronic diseases.

Key regions: Japan, China, Europe, Australia, Canada

Market

Region

Region comparison

Currency

Analyst Opinion

The Prescription Drugs (Pharmacies) market in Central Asia has been experiencing significant growth in recent years.

Customer preferences: Customers in Central Asia have shown a growing preference for prescription drugs, as they seek effective treatment for various health conditions. This preference is driven by an increasing awareness of the benefits of prescription medications and a growing trust in the healthcare system. Additionally, the aging population in Central Asia has contributed to the rising demand for prescription drugs, as older individuals tend to require more medical attention and treatment.

Trends in the market: One of the key trends in the Prescription Drugs (Pharmacies) market in Central Asia is the expansion of pharmacy chains. As the demand for prescription drugs continues to rise, pharmacy chains have been expanding their presence in the region to cater to the growing customer base. This trend has been driven by the need to provide convenient access to prescription medications and to offer a wider range of products and services. Another trend in the market is the increasing use of e-commerce platforms for purchasing prescription drugs. Online pharmacies have gained popularity in Central Asia, as they offer convenience and accessibility to customers. This trend has been further accelerated by the COVID-19 pandemic, which has led to an increase in online shopping and a greater emphasis on contactless transactions.

Local special circumstances: Central Asia is a region with diverse healthcare systems and varying levels of access to healthcare services. In some countries, there may be limited availability of prescription drugs, particularly in rural areas. This creates a challenge for customers in accessing the medications they need. However, efforts are being made to improve the distribution and availability of prescription drugs in these areas, such as through mobile clinics and telemedicine services.

Underlying macroeconomic factors: The growth of the Prescription Drugs (Pharmacies) market in Central Asia is supported by several macroeconomic factors. The region has been experiencing overall economic growth, which has led to an increase in disposable income and a higher standard of living. This has allowed individuals to afford prescription medications and invest in their healthcare. Furthermore, governments in Central Asia have been investing in healthcare infrastructure and implementing healthcare reforms to improve access to quality healthcare services. These efforts have contributed to the growth of the Prescription Drugs (Pharmacies) market by creating a favorable environment for the development of the healthcare industry. In conclusion, the Prescription Drugs (Pharmacies) market in Central Asia is witnessing significant growth due to customer preferences for prescription drugs, the expansion of pharmacy chains, the increasing use of e-commerce platforms, local special circumstances, and underlying macroeconomic factors. This market is expected to continue to grow in the coming years as the demand for prescription medications continues to rise and efforts are made to improve healthcare access and infrastructure in the region.

Methodology

Data coverage:

The data encompasses B2C enterprises. Figures are based on offline and online spending by consumers, including VAT. Not included are B2B and B2G sales, or other pharmaceutical sales through hospitals or retail stores such as supermarkets.

Modeling approach:

Market sizes are determined through a bottom-up approach, building on specific predefined factors for each market market. As a basis for evaluating markets, we use industry associations, third-party studies and reports and survey results from our primary research (e.g., the Statista Global Consumer Survey). In addition, we use relevant key market indicators and data from country-specific associations, such as healthcare expenditure per country, consumer healthcare spending, GDP and internet penetration. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the relevant market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. For forecasting digital trends such as the online-pharmacy sales share we use exponential trend smoothing and the s-curve method. The main drivers are healthcare expenditure per country and consumer healthcare spending.

Additional notes:

The data is modeled using current exchange rates. The impact of the COVID-19 pandemic and the Russia-Ukraine war are considered at a country-specific level. The market is updated twice a year. GCS data is reweighted for representativeness.